Skip to content

Tropisetron on Postoperative Pain

Tropisetron on Postoperative Pain in Women After Gynaecological Laparoscopy

Status
Completed
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01304953
Enrollment
296
Registered
2011-02-28
Start date
2010-01-31
Completion date
2010-12-31
Last updated
2011-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pain, Postoperative

Keywords

General anaesthetics, gynaecological laparoscopy, anaesthetic i.v., propofol, anaesthetic volatile, evoflurane, antiemetics, reopisetron, postoperative pain

Brief summary

The role of 5-HT3A receptors in nociceptive processing has been demonstrated in several animal models. However, studies in human volunteers have not been reported except for one recent study suggesting that ondansetron could alleviate propofol-induced nociception. Previous studies demonstrated that patients anaesthetized with sevoflurane have more pain than those anaesthetized with propofol. And we further posit that the difference is due to the nociceptive processing induced by the action of 5-HT3A receptors. In this prospective, randomized, double-blind, placebo-controlled study, we assessed the analgesic action of a 5-HT3A receptor antagonist (tropisetron) in women after gynaecological laparoscopy under general anaesthesia maintained with either sevoflurane or propofol.

Interventions

DRUGGroup P+P

In this arm, anaesthesia was maintained with propofol and remifentanil (0.1 μg kg-1 min-1), and primary anaesthetic namely propofol was titrated to maintain intraoperative BIS values between 45 and 55. If the patient did not respond to increases in the level of primary anaesthetic, additional doses of remifentanil up to 0.2 μg kg-1 min-1 were permitted to provide a more cardio-stable anaesthesia. Patients in this arms received saline placebo i.v. after the induction of anaesthesia.

DRUGGroup P+T

In this arm, anaesthesia was maintained with propofol and remifentanil (0.1 μg kg-1 min-1), and primary anaesthetic namely propofol was titrated to maintain intraoperative BIS values between 45 and 55. If the patient did not respond to increases in the level of primary anaesthetic, additional doses of remifentanil up to 0.2 μg kg-1 min-1 were permitted to provide a more cardio-stable anaesthesia. Patients in this arms received tropisetron 2 mg i.v. after the induction of anaesthesia.

DRUGGroup S+P

In this arm, anesthesia was maintained by sevoflurane and remifentanil (0.1 μg kg-1 min-1), and primary anaesthetic namely sevoflurane was titrated to maintain intraoperative BIS values between 45 and 55. If the patient did not respond to increases in the level of primary anaesthetic, additional doses of remifentanil up to 0.2 μg kg-1 min-1 were permitted to provide a more cardio-stable anaesthesia. Patients in this arms received saline placebo i.v. after the induction of anaesthesia.

DRUGGroup S+T

In this arm, anesthesia was maintained by sevoflurane and remifentanil (0.1 μg kg-1 min-1), and primary anaesthetic namely sevoflurane was titrated to maintain intraoperative BIS values between 45 and 55. If the patient did not respond to increases in the level of primary anaesthetic, additional doses of remifentanil up to 0.2 μg kg-1 min-1 were permitted to provide a more cardio-stable anaesthesia. Patients in this arms received tropisetron 2 mg i.v. after the induction of anaesthesia.

Sponsors

Huazhong University of Science and Technology
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
FEMALE
Age
18 Years to 50 Years
Healthy volunteers
No

Inclusion criteria

* female patients * American Society of Anaesthesiologists Physical Status (ASA-PS) I or II * undergoing selective gynaecological laparoscopies for infertilities

Exclusion criteria

* aged under 18 years old * body mass index (BMI) \> 30 * history of cardiovascular disease * history of respiratory disease * history of neurologic disease * history of chronic antidepressants * history of anxiolytics * history of chronic analgesics intake * participating in other studies

Design outcomes

Primary

MeasureTime frameDescription
Postoperative pain at restAt 0.5 postoperative hourThe primary outcome was the postoperative pain at rest assessed by numeric analog score (NAS, where 0 indicates no pain, and 10 indicates the most severe pain) immediately after awaking.

Secondary

MeasureTime frameDescription
Postoperative pain at restAt 2,4,6,8,10,12,14,16,18,20,22,24 postoperative hoursThe patients were instructed to give the number that represented the pain level at rest soon after awakening, the first 30 min postoperatively, and every 2 hours within the first 24 postoperative hours.
Intraoperative hemodynamic valuesAt 5, 10,15,20,25,30 min after induction and 30, 25, 20, 15,10,5 min before last sutureHeart rate and mean arterial pressure (MAP) every 5 min within 30 min after induction and 30 min before last suture
Postoperative shiveringAt 24 hour postoperativellyThe incidence of shiver within 24 h was recorded.
The incidence of postoperative nausea and vomiting (PONV)At 24 hour postoperativellyThe incidence of postoperative nausea and vomiting (PONV) was recorded at 24 h after surgery.
Quality of Recovery Score 40At 24 postoperative hourQuality of Recovery Score 40 was determined at 24 hours postoperativelly

Countries

China

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026